NCT00727038View on ClinicalTrials.gov

Lucentis for New Onset Neovascular Glaucoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 4, 2008

Primary Completion Date

May 15, 2009

Study Completion Date

May 15, 2009

Conditions
GlaucomaNew Onset GlaucomaNeovascular GlaucomaNew Onset Neovascular Glaucoma
Interventions
DRUG

Ranibizumab (Lucentis)

0.5 mg ranibizumab intravitreal injection single dose administration

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Illinois at Chicago

OTHER

NCT00727038 - Lucentis for New Onset Neovascular Glaucoma | Biotech Hunter | Biotech Hunter